uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026)
uniQure's (QURE) quarterly Net Income towards Common Stockholders came in at -$53.5 million in Q1 2026, down 22.68% year-on-year from -$69.2 million in Q1 2025, and down 425.48% quarter-over-quarter from $16.4 million in Q4 2025.
uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
uniQure's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$53.5 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 22.68% year-over-year to -$53.5 million in Q1 2026; TTM through Mar 2026 was -$154.2 million, a 29.11% increase from a year earlier, with the FY2025 full-year figure at -$199.0 million, up 16.94% from the prior year.
- Net Income towards Common Stockholders fell to -$53.5 million in Q1 2026 per QURE's latest filing, from $16.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $16.4 million in Q4 2025 and bottomed at -$89.6 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$53.5 million (2026), against an average of -$51.3 million.
- Across the five-year window, Net Income towards Common Stockholders sank 1175.45% in 2023 and soared 122.45% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $6.8 million in 2022, then sank by 1175.45% to -$73.2 million in 2023, then dropped by 0.08% to -$73.3 million in 2024, then soared by 122.45% to $16.4 million in 2025, then tumbled by 425.48% to -$53.5 million in 2026.
- Per Business Quant, the three latest QURE Net Income towards Common Stockholders figures stand at -$53.5 million (Q1 2026), $16.4 million (Q4 2025), and -$79.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | uniQure | 2.41 Bn | 2.41 Bn | 3.34 Mn | -53.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | 16.45 Mn |
| Sep 30, 2025 | -79.42 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -73.26 Mn |
| Sep 30, 2024 | -44.38 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | -73.21 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | 8.21 Mn |
| Sep 30, 2021 | -36.53 Mn |
| Jun 30, 2021 | 399.47 Mn |